Abstracts tagged "measure and systemic lupus erythematosus (SLE)"

Abstract Number: 1615 • 2017 ACR/ARHP Annual Meeting
Assessment of a Cognitive Impairment Measure in Systemic Lupus Erythematosus
Nicole Davidson¹, Alexa Meara², Holly Steigelman³, Songzhu Zhao⁴, Guy Brock⁵, Wael Jarjour⁶, Brad H. Rovin⁷, Samir parikh⁴, Hareth M. Madhoun⁸, Lee Hebert⁹, Isabelle Ayoub⁴ and Stacy P. Ardoin¹⁰, ¹The Ohio State University, The Ohio State University, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴The Ohio State University, Columbus, OH, ⁵Department of Biomedical Informatics and Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, ⁷Ohio State University Medical Center, Columbus, OH, ⁸Rheumatology/Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁹Medicine, Ohio State University Medical Center, Columbus, OH, ¹⁰Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: : Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease which can impact the central nervous system in multiple ways, including development of cognitive…
Abstract Number: 1623 • 2017 ACR/ARHP Annual Meeting
Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By a Comprehensive Neuropsychological Battery
Zahi Touma¹, Robin Green², Carmela Tartaglia³, Lesley Ruttan⁴, Sabrina Lombardi⁴, Nicole Anderson⁵, Jiandong Su⁶, Kenneth Colosimo⁶, Michelle Vitti⁶, Dennisse Bonilla⁶, Joan E. Wither⁵, Marvin J. Fritzler⁷ and Dorcas Beaton⁸, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada, ³University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁴Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada, ⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neurobehavioural manifestation of SLE. In our recent systematic review, the prevalence of CI was 38% (95% CI: 33-43%)…
Abstract Number: 2958 • 2017 ACR/ARHP Annual Meeting
Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus
Hermine I. Brunner¹, Michael J. Holland², Michael W. Beresford³, Nicolino Ruperto⁴, Stacy P. Ardoin⁵, Simone Appenzeller⁶, Clovis A Silva⁷, Glaucia V. Novak⁷, Daniela M. Lourenço⁸, Francisco Flores⁹, Beatrice Goilav¹⁰, Scott E. Wenderfer¹¹, Deborah M. Levy¹², Angelo Ravelli¹³, Raju Khubchandani¹⁴, Tadej Avcin¹⁵, Marisa S. Klein-Gitelman¹⁶, Brian M. Feldman¹⁷ and Jun Ying¹⁸, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³On Behalf of the UK JSLE Study Group, Liverpool, United Kingdom, ⁴Istituto Giannina Gaslini, Genoa, Italy, ⁵Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ⁷Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁸Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁹Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ¹¹Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ¹²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹³University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁴Department of Paediatrics, Jaslok Hospital and Research Center, Mumbai, India, ¹⁵Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ¹⁶Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ¹⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is characterized by changing disease activity: episodes of improvement are often followed by episodes of worsening, i.e. flares. Considering…
Abstract Number: 794 • 2016 ACR/ARHP Annual Meeting
Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)
Zahi Touma¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: It is challenging to describe disease activity in SLE in the context of multiple levels of glucocorticoids (GC) treatment. We aim to develop and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].